Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASH 2023 | Risk of transformation by frontline management in FL and MZL: a US population-based analysis

Juan Alderuccio • 11 Dec 2023
ASH 2023
Diffuse Large B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma

Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, Miami, FL, comments on a US population-based analysis of incidence and risk factors for high-grade transformation (HGT) in patients with follicular lymphoma (FL) or subtypes of marginal zone lymphoma (MZL) (splenic, nodal, and extranodal), with either surveillance or treatment as initial strategies. Outcomes varied between these malignancies, with the risk of HGT into diffuse large B cell lymphoma (DLBCL) and overall survival (OS) post-HGT differing depending on whether frontline treatment was administered. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research Funding: Genmab, ADC Therapeutics, BeiGene
Consultancy: Abbvie, ADC Therapeutics, Genentech, Regeneron

More from Juan Alderuccio

Bringing bispecifics into everyday practice in LBCL: overcoming toxicity challenges
0:49
Bringing bispecifics into everyday practice in LBCL: overcoming toxicity challenges
Juan Alderuccio • 11 Sep 2026
Treatment options for patients with R/R DLBCL who progress after CAR-T and bispecifics
1:03
Treatment options for patients with R/R DLBCL who progress after CAR-T and bispecifics
Juan Alderuccio • 11 Sep 2026
Emerging therapies in frontline and R/R FL: CELMoDs, BCL6 degraders, and bispecific antibodies
1:32
Emerging therapies in frontline and R/R FL: CELMoDs, BCL6 degraders, and bispecific antibodies
Juan Alderuccio • 11 Sep 2026
Key factors guiding CAR-T vs bispecific selection in FL: clinical and patient considerations
1:03
Key factors guiding CAR-T vs bispecific selection in FL: clinical and patient considerations
Juan Alderuccio • 11 Sep 2026

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals